CHCWM – Cancer & Hematology Centers of West Michigan

Cardiff Oncology CRDF-01E (EAP)

An Expanded Access Program of Onvansertib in Combination with FOLFIRI and Bevacizumab for the Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

MERCK (KeyVibe-008)

  A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer PI: Dr. Chen Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center

Merck MK-7339-003 (LYNK-003)

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003) Principal Investigator: Dr. Sreenivasa Chandana For more information on this

Merck MK7902-015 (LEAP015)

  A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK 7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015) PI: Dr. Chandana Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton

MERCK MK7864A-007

  A Randomized, Double-Blind, Phase 3 Study of MK-7684A Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer PI: Dr Chen Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion

TH1902-CTR-0001 (Theratechnologies, Inc.)

A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors and Expansion in Patients with Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer and Pancreatic Cancer